Table 1:
Baseline therapy in heart failure clinical trials
| Trial | Beta blockers | ACEi/ARB | MRA | ISDN | Digoxin | Loop diuretic |
|---|---|---|---|---|---|---|
| V-Heft [64] | 35% | 93% | - | - | 67% | 85% |
| CONSENSUS [65] | 3% | - | 52% | 46% | 93% | 98% |
| SOLVD Treatment Trial [11] | 8% | - | - | 51% | 67% | - |
| MERIT-HF [13] | - | 96% | - | - | 64% | 90% |
| COPERNICUS [66] | - | 97% | 20% | - | 66% | 99% |
| COMET [67] | - | 92% | 11% | 33% | 59% | 99% |
| RALES [14] | 11% | 95% | - | - | 74% | 100% |
| CHARM-Alternative [68] | 55% | - | 24% | 43% | 45% | 85% |
| A-HeFT [16] | 74% | 87% | 39% | - | 60% | 90% |
| EMPHASIS [69] | 87% | 93% | - | - | 27% | 85% |
ACEi/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; ISDN: Isosorbide dinitrate